Lacosamid Puren (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, stabilizing hyper‑excitable neuronal membranes and reducing the spread of abnormal electrical activity that can trigger seizures.

The dosage of lacosamide is individualized; a qualified prescriber determines the appropriate dose based on the patient’s clinical condition, response, and any relevant laboratory parameters.

Lacosamide is classified as Pregnancy Category B, indicating no evidence of risk in animal studies but limited human data. Use only if clearly needed, and discuss potential benefits and risks with a healthcare professional. Breastfeeding decisions should also be made in consultation with a clinician.

To request Lacosamid Puren, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lacosamide’s unique mechanism—enhancing slow sodium‑channel inactivation—differs from many traditional antiepileptics that target fast inactivation. This can provide additive seizure control when combined with other agents, and it is generally well‑tolerated, though individual response and side‑effect profiles vary among patients.

Lacosamid Puren should be stored below 25 °C in its original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and do not use it after the expiration date.

Lacosamid Puren is taken orally, usually with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water; it is not intended for crushing or chewing unless specifically advised.

Serious adverse events, though rare, include suicidal thoughts or behavior, severe skin reactions such as Stevens‑Johnson syndrome, blood dyscrasias, cardiac conduction abnormalities (e.g., PR‑interval prolongation), and hypersensitivity reactions. Patients should seek immediate medical attention if any of these occur.

Lacosamide is contraindicated in patients with known hypersensitivity to lacosamide or any of its excipients. Caution is also advised for individuals with significant cardiac conduction disorders, severe hepatic impairment, or those taking interacting medications that cannot be safely managed.